Mainstay Medical announces € 30 million fundraising
on 17/06/2016 12:43
New capital to support European Commercialisation and US PMA clinical trial
Read more
Read more
mainstay
Mainstay Medical full year 2015 preliminary results and business update
on 16/02/2016 14:15
Additional data confirm positive results for Clinical Trial of ReActiv8®
on 04/12/2015 10:24
Additional data confirm clinically important, statistically significant, and lasting improvement in pain, disability, and quality of life for people with Chronic Low Back Pain and limited treatment options
Read more
Read more
Mainstay Medical Applies for CE Mark for ReActiv8®
on 02/11/2015 11:38
A key step towards European commercialisation of innovative treatment of chronic low back pain
Read more
Read more
